HomeACADEMIA
ACADEMIA

AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis
(Jun.13.2017)

The fixed-dose combination therapy containing the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (G/P) achieved in a Japanese PIII study a sustained virologic response at 12 weeks post treatment (SVR12) and 24 weeks post treatment (SVR24) of 100% in genotype 1 hepatitis C patients with compensated cirrhosis (treated for 12 weeks). The data were presented at the annual meeting of the Japan Society of Hepatology held in Hiroshima on June 8-9 ...
(LOG IN FOR FULL STORY)

News Calendar